SSRIs and the female brain - Potential for utilizing steroid-stimulating properties to treat menstrual cycle-linked dysphorias

Journal of Psychopharmacology

Volumn 27, Issue 12, 2013, Pages 1180-1185

  Lovick, Thelma ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

allopregnanolone; anxiety; female brain; fluoxetine; neurosteroid replacement; SSRIs

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; 4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID RECEPTOR; FLUOXETINE; PROGESTERONE; SEROTONIN UPTAKE INHIBITOR; ELTANOLONE;

ARTICLE; BEHAVIOR CHANGE; BRAIN; CATAMENIAL EPILEPSY; DISEASE ASSOCIATION; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DYSPHORIA; HORMONAL THERAPY; HORMONE RELEASE; HUMAN; LOW DRUG DOSE; LUTEAL PHASE; MENSTRUAL CYCLE; NERVE CELL EXCITABILITY; NONHUMAN; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; SEIZURE; TRANQUILIZING ACTIVITY; TREATMENT WITHDRAWAL; WITHDRAWAL SEIZURE; ANIMAL; DOSE RESPONSE; DRUG EFFECTS; EPILEPSY; FEMALE; METABOLISM; NERVE CELL; PATHOPHYSIOLOGY; PHYSIOLOGY; RAT; SECRETION (PROCESS);

ANIMALS; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; EPILEPSY; FEMALE; FLUOXETINE; GABAERGIC NEURONS; HUMANS; MENSTRUAL CYCLE; NEURONS; PREGNANOLONE; PREMENSTRUAL SYNDROME; PROGESTERONE; RATS; SEROTONIN UPTAKE INHIBITORS;

EID: 84887847298     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881113490327     Document Type: Article

References (57)

1. Amsterdam JD, Hornig-Rohan M, Maislin G. Efficacy of alprazolam in reducing fluoxetine-induced jitteriness in patients with major depression. J Clin Psychiatry. 1994 ; 55: 394-400
2. Belelli D, Lambert JJ. Neurosteroids: Endogenous regulators of the GABA(A) receptor. Nat Rev Neurosci. 2005 ; 6: 565-575
3. Birkett MA, Shinday NM, Kessler EJ, et al. Acute anxiogenic-like effects of selective serotonin reuptake inhibitors are attenuated by the benzodiazepine diazepam in BALB/c mice. Pharmacol Biochem Behav. 2011 ; 98: 544-551
4. Brack KE, Lovick TA. Neuronal excitability in the periaqueductal grey matter during the estrous cycle in female Wistar rats. Neuroscience. 2007 ; 144: 325-335
5. Brown J, O'Brien PM, Majoribanks J, et al. Selective serotonin reuptake blockers for premenstrual syndrome. Cochrane Database Sys Rev. 2009 ;:
6. Butcher RL, Collins WE, Fugo NW. Plasma concentration of LH, FSH, prolactin, progesterone and estradiol-17beta throughout the 4-day estrous cycle of the rat. Endocrinology. 1974 ; 94: 1704-1708
7. Corpéchot C, Young J, Calvel M, et al. Neurosteroids: 3 alpha-hydroxy-5 alpha-pregnan-20-one and its precursors in the brain, plasma, and steroidogenic glands of male and female rats. Endocrinology. 1993 ; 133: 1003-1009
8. DevallAJFryJPHonourJW. (2011) Brain progesterone metabolism in rats following acte fluoxetine treatment: Sex differences and anxiolytic effects in females. Program no. 281.1.2011 Neuroscience meeting.
9. Devall AJ, Liu ZW, Lovick TA. Hyperalgesia in the setting of anxiety: Sex differences and effects of the oestrous cycle in Wistar rats. Psychoneuroendocrinology. 2009 ; 34: 587-596
10. Doornbos B, Fokkema DS, Molhoek M, et al. Abrupt rather than gradual hormonal changes induce postpartum blues-like behavior in rats. Life Sci. 2009 ; 84: 69-74
11. Farrant M, Nusser Z. Variations on an inhibitory theme: phasic and tonic activation of GABA(A) receptors. Nat Rev Neurosci. 2005 ; 6: 215-229
12. Gangisetty O, Reddy DS. Neurosteroid withdrawal regulates GABA-A receptor α4-subunit expression and seizure susceptibility by activation of progesterone receptor-independent early growth response factor-3 pathway. Neuroscience. 2010 ; 170: 865-880
13. Griffin LD, Mellon SH. Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes. Proc Natl Acad Sci USA. 1999 ; 96: 13512-13517
14. Griffiths J, Lovick T. Withdrawal from progesterone increases expression of alpha4, beta1, and delta GABA(A) receptor subunits in neurons in the periaqueductal gray matter in female Wistar rats. J Comp Neurol. 2005a ; 486: 89-97
15. Griffiths JL, Lovick TA. GABAergic neurones in the rat periaqueductal grey matter express alpha4, beta1 and delta GABAA receptor subunits: Plasticity of expression during the estrous cycle. Neuroscience. 2005b ; 136: 457-466
16. Gulinello M, Gong QH, Li X, et al. Short-term exposure to a neuroactive steroid increases α4 GABAA receptor subunit levels in association with increased anxiety in the female rat. Brain Res. 2001 ; 910: 55-66
17. Gulinello M, Gong QH, Smith SS. Progesterone withdrawal increases the alpha4 subunit of the GABA(A) receptor in male rats in association with anxiety and altered pharmacology - a comparison with female rats. Neuropharmacology. 2002 ; 43: 701-174
18. Gulinello M, Orman R, Smith SS. Sex differences in anxiety, sensorimotor gating and expression of the alpha4 subunit of the GABAA receptor in the amygdala after progesterone withdrawal. Eur J Neurosci. 2003 ; 17: 641-648
19. Herzog AG, Fowler KM, Smithson SD, et al. Progesterone Trial Study Group. Progesterone vs placebo therapy for women with epilepsy: A randomized clinical trial. Neurology. 2012 ; 78: 1959-1966
20. Higashi T, Naguray Y, Shimada K, et al. Studies on neurosteroids XXVI. Fluoxetine-evoked changes in rat brain and serum levels of neuroactive Androgen, 5a-Androstane-3a,17b diol. Biol Pharm Bull. 2009 ; 32: 1636-1638
21. Holzbauer M, Birmingham MK, De Nicola AF, et al. In vivo secretion of 3 alpha-hydroxy-5 alpha-pregnan-20-one, a potent anaesthetic steroid, by the adrenal gland of the rat. J Steroid Biochem. 1985 ; 22: 97-102
22. Hsu FC, Smith SS. Progesterone withdrawal reduces paired-pulse inhibition in rat hippocampus: Dependence on GABA(A) receptor alpha4 subunit upregulation. J Neurophysiol. 2003 ; 89: 186-198
23. Katz MM, Tekell JL, Bowden CL, et al. Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression. Neuropsychopharmacology. 2004 ; 29: 566-579
24. Lambert JJ, Belelli D, Peden DR, et al. Neurosteroid modulation of GABAA receptors. Prog Neurobiol. 2003 ; 7 (1). 67-80
25. Lerma J, Herranz AS, Herreras O, et al. In vivo determination of extracellular concentration of amino-acids in the rat hippocampus: A method based on brain dialysis and computerised analysis. Brain Res. 1986 ; 384: 145-155
26. Lipinski JF, Mallya G, Zimmerman P, et al. Fluoxetine-induced akathasia: Clinical and theoretical implications. J Clin Psychiatr. 1989 ; 50: 339-342
27. Lovick TA, Griffiths JL, Dunn SM, et al. Changes in GABA(A) receptor subunit expression in the midbrain during the oestrous cycle in Wistar rats. Neuroscience. 2005 ; 131: 397-405
28. Marx CE, Shampine LJ, Khisti RT, et al. Olanzapine and fluoxetine administration and coadministration increase rat hippocampal pregnenolone, allopregnanolone and peripheral deoxycorticosterone: Implications for therapeutic actions. Pharmacol Biochem Behav. 2006 ; 84: 609-617
29. Mody I. Distinguishing between tonic and phasic conductances. Neurochem Res. 2001 ; 26: 907-913
30. Mody I. Aspects of the homeostatic plasticity of GABAA receptor-mediated inhibition. J Physiol. 2005 ; 56: 237-246
31. Moran M, Smith SS. Progesterone withdrawal 1: Proconvulsant effects. Brain Res. 1998 ; 807: 84-90
32. Nappi RE, Petyraglia F, Luisi S, et al. Serum allopregnanolone levels in women with postpartum "blues". Obstet Gynaecol. 2001 ; 97: 77-80
33. Nelson M, Pinna G. S-norfluoxetine microinfused into the basolateral amygdala increases allopregnanolone levels and reduces aggression in socially isolated mice. Neuropharmacology. 2011 ; 60: 1154-1159
34. Pinna G. A mouse model relevant for PTSD, selective brain steroidogenic stimulants (SBSSs) improve behavioral deficits by normalizing allopregnanolone biosynthesis. Behav Pharmacol. 2010 ; 21: 438-450
35. Pinna G, Costa E, Guidotti A. SSRIs act as selective brain steroidogenic stimulants (SBSSs) at low doses that are inactive on 5-HT reuptake. Curr Opin Pharmacol. 2009 ; 9: 24-30
36. Rasmusson AM, Pinna G, Pallival P, et al. Decreased cerebrospinal fluid allopregnanolone levels in women with post traumatic stress disorder. Biol Psychiat. 2006 ; 60: 704-713
37. Ravinder S, Pillai A, Chattarji S. Cellular correlates on enhanced anxiety caused by acute treatment with the selective serotonin reputake inhibitor in rats. Front Behav Neurosci. 2011 ; 5: 88
38. Ravindran LN, Woods SA, Steiner M, et al. Symptom-onset dosing with citalopram in the treatment of premenstrual dysphoric disorder (PMDD): A case series. Arch Womens Ment Health. 2007 ; 10: 125-127
39. Reddy DS. The role of neurosteroids in the pathophysiology and treatment of catamenial epilepsy. Epilepsy Res. 2009 ; 85: 1-30
40. Reddy DS. The testosterone-derived neurosteroid androstanediol is a positive allosteric modulator of GABAA receptors. J Pharmacol Exp Therap. 2010 ; 334: 1031-1041
41. Reddy DS. Neuroendocrine aspects of catamenial epilepsy. Horm Behav. 2013 ; 63: 254-266
42. Romeo E, Strohle A, Spalletta G, et al. Effects of antidepressant treatment on neuroactive steroids in major depression. Am J Psychiat. 1998 ; 155: 910-913
43. Salchner P, Singewald N. Neuroanatomical substrates involved in the anxiogenic-like effect of acute fluoxetine treatment. Neuropharmacology. 2002 ; 43: 1238-1248
44. SantosJMDevallAJLiK. (2012) Short-term administraion of fluoxetine produces anxiolytic effects in femlae rats during late diestrus via a mechanism that elevates brain conentrations of the neuroactive steroid allopregnanolone but does not alter extracellular 5-HT. Program no. 359.03.2012 Neuroscience meeting.
45. Silva RC, Brandão ML. Acute and chronic effects of gepirone and fluoxetine in rats tested in the elevated plus-maze: An ethological analysis. Pharmacol Biochem Behav. 2000 ; 65: 209-216
46. Smith SS, Gong QH, Li X, et al. Withdrawal from 3alpha-OH-5alpha-pregnan- 20-One using a pseudopregnancy model alters the kinetics of hippocampal GABAA-gated current and increases the GABAA receptor alpha4 subunit in association with increased anxiety. J Neurosci. 1998 ; 18: 5275-5284
47. Steiner M. Premenstrual syndromes. Ann Rev Med. 1997 ; 48: 447-455
48. Steiner M. Premenstrual syndrome and premenstrual dysphoric disorder: Guidelines for management. J Psychiatry Neurosci. 2000 ; 25: 459-468
49. Steiner M, Ravindran AV, LeMelledo JM, et al. Luteal phase administration of paroxetine for the treatment of premenstrual dysphoric disorder: A randomized, double-blind, placebo-controlled trial in Canadian women. J Clin Psychiat. 2008 ; 69: 991-998
50. Strohle A, Romeo E, Jermann B, et al. Concentrations of 3α-reduced neuroactive steroids and their precursors in plasma of patients with major depression and after clinical recovery. Biol Psychiat. 1999 ; 45: 274-277
51. Trauger JW, Jiang A, Stearns BA, et al. Kinetics of allopregnanolone formation catalyzed by human 3 alpha-hydroxysteroid dehydrogenase type III (AKR1C2). Biochemistry. 2002 ; 41: 13451-13459
52. Ugale RR, Mittal N, Hirani K, et al. Essentiality of central GABAergic neuroactive steroid allopregnanolone for anticonvulsant action of fluoxetine against pentylenetetrazole-induced seizures in mice. Brain Res. 2004 ; 1023: 102-111
53. Uzunov DP, Cooper TB, Costa E, et al. Fluoxetine-elicited changes in brain neurosteroid content measured by negative ion mass fragmentography. Proc Natl Acad Sci USA. 1996 ; 93: 12599-12604
54. Uzunova V, Sampson L, Uzunov DP. Relevance of endogenous 3α reduced neurosteroids to depression and antidepressant action. Psychopharmacology. 2006 ; 186: 351-361
55. Uzunova V, Sheline Y, Davis JM, et al. Increase in cerebrospinal fluid content of neurosteroids in patients with unipolar depression who are receiving fluoxetine or fluvoxamine. Proc Natl Acad Sci USA. 1998 ; 95: 3239-3244
56. Wang M. Neurosteroids and GABA-A receptor function. Front Endocrinol (Lausanne). 2011 ; 2: 44
57. Wong DT, Bymaste FP, Engleman EA. Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: Twenty years since its first publication. Life Sci. 1995 ; 57: 411-441